What's Happening?
BUILT Biotechnologies, Inc., based in Charlottesville, Virginia, has been selected as the preferred manufacturing partner for Neochromosome, Inc. clients requiring large-scale DNA builds. Neochromosome is
shifting its focus from DNA services to antibody display and cell engineering platforms, prompting the transition. BUILT's Regenerative DNA Assembly platform, known for its reliability and domestic supply-chain resilience, will support these clients. To ensure continuity and growth, BUILT has expanded its team by appointing Steve Riedmuller as Chief Commercial Officer and Amanda Skeen as Market Development Leader. The company is also relocating its headquarters to North Fork Research Park and increasing its manufacturing capacity to accommodate the expected influx of projects.
Why It's Important?
This transition is significant for the biotechnology industry, as it ensures uninterrupted access to high-fidelity DNA necessary for genome engineering programs. BUILT's expansion and strategic appointments aim to facilitate a seamless transition for Neochromosome's clients, potentially unlocking new genome-engineering breakthroughs. The move highlights the growing demand for outsourced DNA production and the importance of reliable supply chains in biotechnology. Companies involved in genome engineering and synthetic biology stand to benefit from BUILT's enhanced capabilities, while the industry may see increased innovation and efficiency in DNA manufacturing processes.
What's Next?
BUILT Biotechnologies is preparing for the transition by expanding its manufacturing capacity and relocating its headquarters. Former Neochromosome clients have been contacted individually to ensure no disruption to ongoing research programs. BUILT's secure ordering portal will be available to these clients, allowing them to reserve manufacturing capacity through the first quarter of 2026. The company is poised to support the next wave of genome-engineering breakthroughs, with its expanded team and facilities ready to meet rising demand.
Beyond the Headlines
The collaboration between BUILT Biotechnologies and Neochromosome underscores the evolving landscape of DNA manufacturing and the shift towards centralized services. This model eliminates the need for in-house DNA assembly, offering a more efficient and scalable solution for researchers. The transition may also influence other companies in the biotechnology sector to adopt similar strategies, potentially leading to broader industry changes in how DNA manufacturing is approached.
